DH - NASDAQ
Definitive Healthcare Corp.
$0.91
+3.9%Definitive Healthcare Corp., together with its subsidiaries, provides healthcare commercial intelligence in the United States. Its solutions provide information on healthcare providers and their activities to help its customers in the area ranging from product development to go-to-market planning, and sales and marketing execution. The company's platform offers 16 intelligence modules that cover functional areas, such as sales, marketing, clinical research and product development, strategy, talent acquisition, and physician network management. It serves biopharmaceutical and medical device companies, healthcare information technology companies, and healthcare providers; and other diversified companies comprising staffing and commercial real estate companies, financial institutions, and other organizations in the healthcare ecosystem. Definitive Healthcare Corp. was founded in 2011 and is headquartered in Framingham, Massachusetts.
At a Glance
Live Snapshotdh
Stock Based Compensation
Last Annual Value
29.14M
3-Year CAGR
-7%
5-Year CAGR
76%
10-Year CAGR
16%
Definitive Healthcare Corp. Competitors Analysis of Stock Based Compensation
| Company | Stock Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Definitive Healthcare Corp. NASDAQ:DH | 29.14M | -15.8% | 24.0% | N/A | |
 Simulations Plus, Inc. NASDAQ:SLP | 6.35M | 9.6% | 18.2% | 33.7% | |
 TruBridge, Inc. NASDAQ:TBRG | 8.66M | 38.3% | 9.7% | N/A | |
 Editas Medicine, Inc. NASDAQ:EDIT | 10.00M | -20.4% | -25.4% | -5.1% | |
 Nakamoto Inc. NASDAQ:NAKA | 2.36M | 78.5% | N/A | N/A | |
 Cabaletta Bio, Inc. NASDAQ:CABA | 20.94M | 22.7% | 29.3% | N/A | |
 Kyverna Therapeutics, Inc. NASDAQ:KYTX | 10.08M | 65.6% | 6.8% | N/A | |
 Lyell Immunopharma, Inc. NASDAQ:LYEL | 41.83M | -3.9% | -7.6% | N/A | |
 Neumora Therapeutics, Inc. Common Stock NASDAQ:NMRA | 29.88M | 20.1% | 47.5% | N/A | |
 National Research Corporation NASDAQ:NRC | 3.31M | 52.4% | 39.7% | 5.6% | |
 Owens & Minor, Inc. NYSE:OMI | 26.84M | 4.9% | 1.4% | 8.3% |
Definitive Healthcare Corp. Fair Value Envelope
Related Guides
Continue your DH research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.